NEW YORK, NY--(Marketwire - Mar 4, 2013) - Immunovative Inc. (
The articles of amendment were submitted to the State of Florida on February 22, 2013 and the corporate action application was submitted to FINRA on February 28, 2013. After receiving the necessary approvals, the Company will be called Tauriga Sciences, Inc ("Tauriga"). In addition the Company will request, in connection with the FINRA process, a new trading symbol to reflect the corporate name change and will disclose the new symbol as soon as possible.
The Company is also constructing its new corporate website, which will exist under the following new URL address: (www.taurigasciences.com). As soon as the new corporate website is launched, the Company will notify shareholders through a press release. As previously stated, the Company anticipates that it will continue to operate in the biotechnology or medical device sector.
Commenting on the name and symbol change, the Company's CEO Seth M. Shaw commented, "The Company and its management are excited to capitalize on potential opportunities available to us, with the goal of both restoring and creating lasting shareholder value."
About Immunovative Inc.
On February 20, 2013, Immunovative, Inc. filed a Form 8K to notify shareholder that the Company entered into a Settlement Agreement and Release with ITL (the "Settlement Agreement"). The Settlement Agreement resolves all claims brought by the Company against ITL. The Company's current focus is to evaluate potential opportunities in the biotechnology and/or medical device industry, however the Company will consider other potential sectors if deemed in the best interest of shareholders. Additionally on March 04, 2013, the Company announced that it filed for a name and symbol change, such that the Company has changed its name to Tauriga Sciences Inc. and is awaiting its new trading symbol. The new corporate website is under construction and shall be launched at a future date under the URL address: www.taurigasciences.com.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.